CAR-T:现在和未来

Kunal Mishra, Shun-Feng Zhou, Jiazhi Sun
{"title":"CAR-T:现在和未来","authors":"Kunal Mishra, Shun-Feng Zhou, Jiazhi Sun","doi":"10.4172/2165-7092.1000154","DOIUrl":null,"url":null,"abstract":"Chimeric antigen receptors (CARs) are recombinant receptors that are expressed on autologous T-cells. CAR-T usage has grown in recent years as a way to combat hematological and solid tumors. The purpose of this review is to describe new studies on CAR-T treatment along with our lab’s ideas on potential uses and pitfalls that could be investigated. The usage of TREG and antiCLTA4 as means for regulating CAR-T will also be looked at along with OX40, CD137 and CD27 receptors as means for increasing the efficacy of the treatment overall. In addition the usage of iCasp9 as a ‘suicide switch’ for the CAR-T treatment and the potential for a 4th generation CAR will be touched upon. Then the review will lead into talks about how such a treatment could be of potential use in treating solid and hematological cancer.","PeriodicalId":89708,"journal":{"name":"Pancreatic disorders & therapy","volume":"68 1","pages":"1-3"},"PeriodicalIF":0.0000,"publicationDate":"2015-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"CAR-T: The Current and the Future\",\"authors\":\"Kunal Mishra, Shun-Feng Zhou, Jiazhi Sun\",\"doi\":\"10.4172/2165-7092.1000154\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Chimeric antigen receptors (CARs) are recombinant receptors that are expressed on autologous T-cells. CAR-T usage has grown in recent years as a way to combat hematological and solid tumors. The purpose of this review is to describe new studies on CAR-T treatment along with our lab’s ideas on potential uses and pitfalls that could be investigated. The usage of TREG and antiCLTA4 as means for regulating CAR-T will also be looked at along with OX40, CD137 and CD27 receptors as means for increasing the efficacy of the treatment overall. In addition the usage of iCasp9 as a ‘suicide switch’ for the CAR-T treatment and the potential for a 4th generation CAR will be touched upon. Then the review will lead into talks about how such a treatment could be of potential use in treating solid and hematological cancer.\",\"PeriodicalId\":89708,\"journal\":{\"name\":\"Pancreatic disorders & therapy\",\"volume\":\"68 1\",\"pages\":\"1-3\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2015-04-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pancreatic disorders & therapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4172/2165-7092.1000154\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pancreatic disorders & therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4172/2165-7092.1000154","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

嵌合抗原受体(CARs)是在自体t细胞上表达的重组受体。近年来,CAR-T作为一种对抗血液病和实体瘤的方法,其使用有所增长。这篇综述的目的是描述CAR-T治疗的新研究,以及我们实验室对潜在用途和可能研究的缺陷的想法。TREG和antiCLTA4作为调节CAR-T的手段也将与OX40、CD137和CD27受体一起被视为提高整体治疗效果的手段。此外,iCasp9作为CAR- t治疗的“自杀开关”的使用以及第四代CAR的潜力也将被提及。然后,该综述将引导讨论这种治疗方法如何在治疗实体癌和血液病方面具有潜在的用途。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
CAR-T: The Current and the Future
Chimeric antigen receptors (CARs) are recombinant receptors that are expressed on autologous T-cells. CAR-T usage has grown in recent years as a way to combat hematological and solid tumors. The purpose of this review is to describe new studies on CAR-T treatment along with our lab’s ideas on potential uses and pitfalls that could be investigated. The usage of TREG and antiCLTA4 as means for regulating CAR-T will also be looked at along with OX40, CD137 and CD27 receptors as means for increasing the efficacy of the treatment overall. In addition the usage of iCasp9 as a ‘suicide switch’ for the CAR-T treatment and the potential for a 4th generation CAR will be touched upon. Then the review will lead into talks about how such a treatment could be of potential use in treating solid and hematological cancer.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信